Acasti Pharma Inc (ACST.V) Q1 2026 Earnings Report

Acasti Pharma reported a Q1 2026 period with no revenue and ongoing operating losses, underscoring the company’s status as an early-stage biotech focused on cardiovascular therapeutics via CaPre. For the quarter, revenue was not reported, gross profit was negative by 2,000 USD, and total operating expenses were 3.088 million USD, yielding an EBIT/EBITDA trajectory that remained deeply negative (EBITDA: -3.36 million; net income: -3.36 million; EPS: -0.21). Management commentary, where available, emphasized strategic partnerships around CaPre as the primary near-term inflection point, although explicit quarterly guidance was not disclosed in the provided data. The company closed the period with a solid cash position of 20.005 million USD and a net cash outflow from operations of 1.801 million USD, contributing to a quarterly net cash burn of 2.128 million USD when including financing activity. Despite the cash runway, the lack of current revenue and sustained losses indicate continued dependence on external funding to advance clinical milestones and partnership arrangements.

From a balance sheet perspective, Acasti carries significant intangible assets and goodwill (intangible assets 41.128 million USD and goodwill 8.138 million USD) relative to total assets (69.805 million USD), alongside a large accumulated deficit (-224.049 million USD). This structure supports a high impairment risk if trial results or partnership milestones fail to materialize. The liquidity position remains favorable with total current assets of 20.525 million USD versus total current liabilities of 2.315 million USD, implying a robust near-term liquidity cushion. However, the earnings power remains out of reach absent a strategic deal or proof-of-concept advancements, making equity financing or milestone partnerships the critical catalysts for value realization.

Key takeaway: the QQ1 2026 result underscores a funding‑dependent narrative typical of early-stage cardiovascular biotech, where liquidity is adequate for now but execution on CaPre partnerships and/or pipeline milestones will determine the sustainability of the business model and equity value.